ReviewMolecular cancer2026
Spatiotemporal dynamics of radioresistance: decoding macrophage-driven radioprotective niches through temporal-spatial reprogramming.
Review in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Within the intricate tumor microenvironment (TME), tumor-associated macrophages (TAMs) engage in dynamic cross-communication with neighboring cellular and acellular components, orchestrating dual pro- and anti-tumorigenic programs, including tumor proliferation, immune suppression, angiogenesis, extracellular matrix remodeling, and metabolic reprogramming. Radiotherapy, while inducing direct tumoricidal effects, paradoxically triggers vascular injury and inflammatory cascades that recruit and reprogram TAM populations. These radiation-educated TAMs subsequently establish therapy-resistant niches through multifaceted mechanisms, driving post-radiation tumor recurrence and treatment failure. Emerging evidence highlights that TAM polarization states critically determine therapeutic outcomes in both standalone radiotherapy and combination regimens with immunotherapy. However, translating TAM-targeting strategies into clinical practice faces substantial biological and technical challenges.In this review, we systematically analyze the spatial-temporal mechanisms underlying radiotherapy-induced TAM recruitment and radioresistance development, with particular emphasis on their bidirectional interactions with tumor cells, immune effectors, hypoxic niches, and stromal cells. Specifically, we map the therapeutic landscape by evaluating promising targets for TAM reprogramming in combination with radiotherapy and/or immune checkpoint blockade. Furthermore, we critically appraise emerging technologies for TAM manipulation in the radioimmunotherapy context, including nanotheranostics and novel therapeutic approaches. Finally, we discuss unresolved mechanistic questions, translational barriers, and strategic opportunities for developing personalized combination therapies that leverage TAM biology to overcome radioresistance. This synthesis provides a conceptual framework for rationally designing next-generation radiosensitization strategies grounded in TME immunomodulation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.